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SUMMARY
Objective: To compare PRISCUS with Beers-Fick in detecting potentially inappropriate 
medication (PIMs) in elderly at their first outpatient geriatric visit. Methods: Retrospec-
tive medical record analysis by PRISCUS and Beers-Fick adapted to Brazilian pharma-
copoeia, comparing the finding of PIMs at the first outpatient geriatric visit by both 
criteria. Results: Cases had mean age of 77.4 ± 7.7 years (64 females and 36 males), and 
mean consumption of 3.9 ± 2.5 drugs. This study found statistical significance for the 
numbers of women using benzodiazepines and men using salicylates. The mean was 
0.5 ± 0.7 PIMs/patient by Beers-Fick criteria and 0.7 ± 0.8 PIMs/patient by PRISCUS. 
Medications most often reported by Beers-Fick criteria were: benzodiazepines, meth-
yldopa and ergot-derived drugs. Medications most often reported by PRISCUS criteria 
were: benzodiazepines, antihypertensive drugs, and tricyclic antidepressants. No statisti-
cal significance was found when the number of elderly patients with PIMs was compared 
between both criteria. Statistical significance was found (PRISCUS versus Beers-Fick) 
for the consumption of long acting benzodiazepines and laxatives. Both criteria do not 
include drugs such as vitamins, herbal medications, and eye drops, reported by a per-
centage of cases. Conclusion: Both criteria are useful to prevent PIMs in the elderly, with 
PRISCUS being more updated and comprehensive, but they are not complete for the 
Brazilian outpatient reality.
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INTRODUCTION
Significant percentages of elderly have several con-
comitant diseases, which leads to the concomitant use 
of three or more medications1-4. In parallel, changes in 
body composition and kidney and liver functions caused 
by natural human aging are observed5. Thus, pharma-
cokinetic and pharmacodynamic interference exists 
among various drugs, some of them prescribed regularly 
in clinical practice5-6. This medication consumption pat-
tern, associated with age-linked diseases and changes, 
constantly triggers side effects and drug interactions 
with serious outcomes for patients in this age group4-8.
Medication intake involves serial steps – prescrip-
tion, communication, dispensation, administration, 
and clinical follow-up –, making it a complex and iat-
rogenic-prone act, particularly in the elderly. A signifi-
cant portion of these adverse events can be prevented at 
the prescription stage9. Lists of potentially inappropriate 
medications (PIMs) – defined as drugs at risk of caus-
ing more side effects than benefits in the elderly – are 
useful aids in clinical practice regarding the preventive 
action. Several lists have been published over the last 
two decades10-15. Versions of Beers criteria10,11 and later, 
Beers-Fick criteria13 have become the most cited and 
used worldwide9,16. However, there is criticism of these 
criteria, particularly regarding their drug scope and 
adaptability to specific pharmacopoeias in each coun-
try9,14-16. In the search for reducing the criticized aspects 
of Beers-Fick criteria, Holt et al.17 defined a PIM list for 
the elderly – termed PRISCUS – primarily to be used in 
Germany. The generated list – a total of 83 drugs in 18 
drug classes – includes comments for clinical practice 
and therapeutic options.
Which list or criteria are used in PIM evaluations 
in Brazil? A survey performed in PubMed on April 23, 
2011 with the following keywords: Beers Fick criteria 
Brazil OR Beers criteria Brazil OR potentially inappro-
priate medication elderly Brazil OR inappropriate pre-
scription elderly Brazil retrieved six articles6,18-22, all of 
them with a methodology based on Beers-Fick criteria13. 
A survey at SciELO, using the same keywords and on 
the same date, located seven articles4,5,18-22; five of which 
had been already retrieved by the former portal18-22 and 
two more4,5, the first of which4 cites another report by 
Beers23 and the second5 comments on the first two ver-
sions of Beers criteria10,11. Thus, no PIM list or criteria 
for the elderly have been developed in Brazil. The studies 
published in Brazil follow a global trend, as they use lit-
erature based on articles produced by Beers et al.10,11,13,23.
Considering the above description, the question 
asked is: would the PRISCUS17 list adapted to Brazilian 
pharmacopoeia be more adequate than Beers-Fick13 cri-
teria to detect PIMs in elderly Brazilian patients?
OBJECTIVES
To compare the PRISCUS17 list with Beers-Fick13 criteria 
to detect PIMs in the elderly assessed at the first outpatient 
geriatric visit.
METHODS
Review of elderly outpatients’ medical records through 
the PRISCUS17 list adapted to Brazilian pharmacopoeia 
(Table 1). The same number of cases and same methodol-
ogy as in a study published in 20061 by the authors regard-
ing the applicability of Beers-Fick criteria17 also adapted to 
Brazilian pharmacopoeia (Table 2) at the first outpatient 
geriatric visit were used.
The patients were attended to by the authors in an out-
patient facility belonging to the Irmandade da Santa Casa 
de Misericórdia de São Paulo between the years 2000 and 
2004. Later on (2005), through analysis of the standard 
history taking used at the institute, the drugs in continu-
ous use on the days preceding the first geriatric assessment 
between 2000 and 2004 were reviewed. Both Beers-Fick13 
criteria and the PRISCUS list17 were used to define PIM 
quantitative and qualitative values. PIM standards for 
the elderly were sequentially compared between the two 
adapted criteria/lists13,17 (Boxes 1 and 2). The expected re-
sult aims to determine the PIM prevalence in elderly at the 
onset of outpatient geriatric follow-up. The statistical anal-
ysis used a chi-squared test (Yates’s and/or Fisher’s exact 
test, both with an alpha of 5.0%), dividing the number of 
cases into females and males and into ages 74 and younger 
and 75 and older. The cases were further divided according 
to the main PIM classes used by both criteria13,17 studied.
The present study is a part of Projects # 344/10 
and 404/10 approved by the local institutional ethics 
committee.
RESULTS
The cases consisted of 100 elderly people (64 females and 36 
males) with a mean age of 77.4 ± 7.7 years and a mean con-
sumption of 3.9 ± 2.5 drugs in continuous use/patient (Ta-
ble 1). Statistical significance was reached for the number 
of women using benzodiazepines and men using salicylates.
By Beers-Fick13 criteria, 0.5 ± 0.7 PIMs/patient and by 
the PRISCUS17 list 0.7 ± 0.8 PIMs/patient were observed. 
The drugs in Beers-Fick13 criteria most often reported by 
the elderly assessed were: benzodiazepines, methyldopa, 
ergot-derived drugs, amitriptyline, and amiodarone. The 
drugs in the PRISCUS17 list most often reported by the 
same patients were: benzodiazepines, antihypertensives, 
tricyclic antidepressants, ergot-derived drugs, and laxa-
tives. No statistical significance could be found upon com-
paring the global number of elderly patients using PIMs 
between both criteria13,17. However, statistical significance 
was found by the PRISCUS17 list versus the Beers-Fick13 
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Box 1 – PRISCUS17 list of potentially inappropriate medications for the elderly adapted to Brazilian pharmacopoeia
Box 2 – Drugs not recommended in the elderly, regardless the diagnosis or clinical condition due to high side effects risk, 
with safer drugs marketed in Brazil being preferentially prescribed by Beers-Fick13 criteria
Thioridazine Amiodarone Chlorpropamide
Barbiturates
(except fenobarbital)
Digoxin > 0.125 mg/day
(except in atrial arrhythmias)
Estrogen therapies 
(oral route)
Benzodiazepines Disopyramide Thyroid extract
Lorazepam > 3.0 mg/day Methyldopa Methyltestosterone
Alprazolam > 2.0 mg/day Clonidine Nitrofurantoin
Chlordiazepoxide Nifedipine Ferrous sulfate
Diazepam Doxazosin Cimetidine
Chlorazepate Dipyridamole Ketorolac
Flurazepam Ticlopidine Ergot and ciclandelata
Fluoxetine (daily) Non-steroidal anti-inﬂammatory drugs Muscle relaxants and antispasmodic drugs
Amitriptyline Indomethacin Carisoprodol
Antihistamine drugs Naproxen Chlorzoxazone
Chlorpheniramine Piroxicam Cyclobenzaprine
Hydroxyzine Laxatives Orphenadrine
Cyproheptadine Bisacodyl Oxybutynin
Tripelenamine Cascara sacred Hyoscyamine
Dexchlorpheniramine Mineral oil Propantheline
Promethazine Appetite supressants Belladona Alkaloids
Prometazina Amphetamines Meperidine
Anti-inﬂammatory drugs Antihistamine drugs Extended-release BZDs
Ketoprofen Clemastine Bromazepam
Etoricoxib Chlorpheniramine Clobazam
Phenylbutazone Dimethindene Chlorazepate
Indomethacin Hydroxyzine Chlordiazepoxide
Meloxicam Triprolidine Diazepam
Piroxicam Antiemetic drugs Flunitrazepam
Antihypertensive drugs Dimenhydrinate Flurazepam
Clonidine Ergotamine and ergot-derived drugs Nitrazepam
Doxazosin Dihydroergocryptine Short-medium-acting BZDs
Methyldopa Ergotamine Alprazolam
Nifedipine Typical neuroleptics Lorazepam > 2mg
Prazosin Clozapine “Z-agents”
Reserpin Fluphenazine Zolpidem > 5 mg
Terazosin Haloperidol > 2 mg Zopiclone > 3.75 mg
Antiplatelets Levomepromazine Other sedatives
Ticlopidine Olanzapine > 10 mg Diphenhydramine
Antiarrhythmic drugs Thioridazine Antiepileptic drugs
Digoxin Tricyclic antidepressants Phenobarbital
Quinidine Amitriptyline Opiates
Sotalol Clomipramine Laxatives
Antibiotics Imipramine Miscellaneous
Nitrofurantoin Maprotoline Pentoxifylline
Muscle relaxants Serotonin reuptake inhibitors Naftidrofuryl
Baclofen Fluoxetine Nicergoline
Antispasmodic drugs MAO inhibitors Piracetam
Oxybutynin Tranylcypromine
Tolterodine
MAO, monoamine oxidase, BZDs, benzodiazepines.
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criteria for long acting benzodiazepine and laxative con-
sumption. Both criteria do not include drugs such as vita-
mins, herbal medicines, and eye drops reported by a per-
centage of cases (Table 1).
DISCUSSION
Periodical review of drugs used by the elderly must be an 
intrinsic part of clinical practice. Several concomitant and 
usually chronic diseases generate a potential for concomi-
tant and significant medication consumption1-4. The asso-
ciation of medication use with pharmacokinetic and phar-
macodynamic aging-linked changes creates conditions 
for a high risk of side effects and drug-drug interactions 
observed in the elderly4-8.
Usually, there is a higher number of females and pa-
tients older than 70 among the elderly in need of a special 
care in drug prescription4,6,20-22. These data were also ob-
served in the present cases and are warranted by the re-
markable female longevity and the progressive multiplicity 
of chronic diseases in older age groups24-27. The mean med-
ication use among the elderly reviewed in this study was 
another parallel outcome correlated with that reported in 
the literature4,6,8,20,22. Thus, lists and/or criteria of inappro-
priate medications for elderly are effective both in detect-
ing use and in avoiding prescription.
The subsequent issue is: which criteria and/or lists 
would be more appropriate to the Brazilian reality, since 
no national tool that meets this clinical practice need 
could be found in the literature?
Potentially inappropriate medication guidelines 
for the elderly, such as Beers-Fick13 criteria, are time-
honored in the literature and used in several countries. 
They are practical and easily memorized, although they 
do not consider local realities as for the standard of 
medications delivered and prescribed to certain popula-
tions9,12,14-16,18,19. The PRISCUS list17, primarily conceived 
for German pharmacopoeia, intends to be wider, as it 
contains drugs not mentioned by the Beers-Fick13 crite-
ria. In the current study, a slight numeric PIM difference 
favoring the list was observed,17 possibly resulting from 
its higher discrimination of drug classes and drugs over 
the Beers-Fick criteria13 (61 versus 52 drugs marketed in 
Brazil – Boxes 1 and 2).
Both PIM evaluation tools detected approximately 21 
drugs in common, notably benzodiazepines, antihyper-
tensive drugs, ergotamine and ergot-derived drugs, laxa-
tives, antiarrhythmic drugs, anti-inflammatory drugs, 
and antidepressants. However, a number of details dif-
ferentiate them, such as the larger number of drugs sepa-
rately cited in the Beers-Fick13 criteria and drug classes 
with no mention to PIMs linked to them in the PRISCUS 
list17. Differences are also noted between them, such as 
in lorazepam contraindicated dosage and no doses for 
alprazolam, fluoxetine, and digoxin13,17. Phenobarbital is 
further contraindicated in the PRISCUS17 list, but there is 
an indication by the Beers-Fick criteria13. Thus, they are 
two useful tools for clinical practice, but attention to a 
few details is recommended when they are used.
Table 1 – Case characteristics obtained by reviewing 100 elderly outpatients’ medical records and main medications or 
pharmacological groups used in these patients
Characteristics Females Males Total p
Mean age (years) 75.0 ± 7.1 78.4 ± 7.9 77.4 ± 7.7 NS
Number of patients 64 36 100 -
On medications 57 32 89 NS
Mean medication consumption 3.7 ± 2.5 4.3 ± 2.5 3.9 ± 2.5 NS
Drug(s) ≤ 74 ≥ 75 Total ≤ 74 ≥ 75 Total
Benzodiazepines 3 18 21 2 2 4 25 0.03*
Vitamins 6 8 14 5 4 9 23 NS
Thiazide diuretics 3 12 15 1 7 8 23 NS
Antidepressants 3 8 11 3 7 10 21 NS
Beta-blockers 2 8 10 5 4 9 19 NS
Salicylates - 5 5 4 8 12 17 0.002*
Statins 1 5 6 4 3 7 13 NS
Cinnarizine-ﬂunarizine 3 5 8 1 3 4 12 NS
Gingko biloba 2 4 6 - 5 5 11 NS
Calcium 5 5 10 1 - 1 11 NS
*females vs. males on medication or not; NS, nonsigniﬁcant.
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The presence of significant percentages of vitamin, cin-
narizine-flunarizine, and Gingko-biloba users in the pres-
ent sample is noteworthy, since both evaluation tools13,17 
did not analyze the potential inappropriateness of these 
drugs. This caution is warranted, since chronic use of an-
tivertigo medication, such as cinnarizine and flunarizine, 
might trigger movement disorders28; the combination of 
Gingko-biloba and salicylates and/or non-steroidal anti-
inflammatory drugs enhances the inhibition of platelet 
aggregation and raises bleeding risk29; and indiscriminate 
vitamin intake shows no evidence of benefits to users30.
CONCLUSION
Both criteria are useful for detecting PIMs in the elderly, 
with PRISCUS list being more updated and comprehen-
sive, but care should be taken – they are not complete for 
the Brazilian outpatient reality.
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